• Call(WhatsApp Us)

    +8615360806100
  • Email Us

    cherry@laeyo.com
  • 广州市花都区花山镇华辉路18号

    微观化妆品创意产业园E栋整栋

GSO 1943:2024 for Facial Skincare: Which Safety and Label Questions Should GCC Buyers Ask?

GSO 1943:2024 gives GCC buyers a shared technical reference for cosmetic products, but it does not give you a single regional passport. Facial skincare still passes through national notification, a local responsible entity, Arabic…

Category: Skincare Sourcing Guides • Author: laeyo • Published: 2026-11-06 • Views: 56

GSO 1943:2024 gives GCC buyers a shared technical reference for cosmetic products, but it does not give you a single regional passport. Facial skincare still passes through national notification, a local responsible entity, Arabic labeling, and — above all — evidence that the formula and pack survive Gulf heat, humidity and transit. The questions below are written so a sourcing manager can forward them to a manufacturer before artwork is locked.

Where GSO 1943:2024 Fits — and Where It Stops

Treat the standard as the common baseline for safety, labeling and ingredient control across the Gulf, then verify each destination separately. The practical sequence matters more than the document title:

  • Market → product classification → responsible entity → formula/ingredient compliance → safety file → notification → label → claim classification → evidence → artwork and web copy. Skipping a step is where projects stall.
  • Saudi Arabia: cosmetic notification runs through the SFDA unified electronic system; SFDA 2024 guidance documents the migration from the older eCosma system to the unified platform (Ghad). The local importer or responsible entity is normally the notifier.
  • UAE and other GCC states/emirates: verify each market individually. A filing accepted in one emirate or country is not evidence for the next.
  • Never accept “GCC-approved” or “worldwide compliant” as a statement. Ask which country, which authority, which notification number, and which document set supports it.

The Two Decisions That Come Before Price

1. Classification: cosmetic or something else?

In Saudi Arabia and across the GCC, a product carrying a medical claim can be classified as a drug rather than a cosmetic. That reclassification cannot be rescued later with more efficacy data — it changes the route, the timeline and often the pack. Facial skincare is the category where this happens most often, because marketing language drifts toward treatment wording.

2. Claims: front of pack, PDP, ads and creator scripts all count

Notification or registration does not automatically approve your marketing claims. Product names, images, before/after visuals and influencer briefs can all create an explicit or implied claim. Build an approved-claims matrix per market and hold copy to it.

Claim wording Classification risk What evidence to request
“Treats acne”, “clears breakouts”, “kills acne bacteria” High — likely drug/therapeutic treatment in GCC markets Written regulatory route decision plus clinical or consumer-use data before any copy is approved
“Reduces the appearance of redness”, “improves the look of uneven tone” Lower — defensible as a cosmetic appearance claim if substantiated Instrumental or consumer study report with protocol, panel size, duration and lab identity
“Hypoallergenic” Moderate — market-specific basis required; a patch test alone is not sufficient Patch test or HRIPT plus a written market-specific substantiation rationale; confirm the wording market by market
“Dermatologist tested”, “clinically proven” Moderate — must be literally true and traceable Study report naming the institute, sample size, dates and the exact claim tested
“Non-comedogenic”, “suitable for sensitive skin” Moderate — needs a defined test method Test protocol and result summary; confirm the method is accepted in the destination market
SPF or UV-protection statements Variable — confirm the pathway with the authority before committing to artwork SPF and UVA test reports from an accredited lab plus a written per-country classification note

Safety Questions Specific to Gulf Conditions

Heat and humidity are the number one technical challenge for skincare in this region. A formula that passes a European stability panel can still separate, weep or discolour in a Dubai warehouse or a parked car in Riyadh.

  • Ask for the stability protocol, not just the conclusion. Request storage conditions (including elevated temperature and humidity), test duration, cycling or freeze–thaw steps, and which parameters were checked (pH, viscosity, odour, colour, emulsion integrity, preservative level).
  • Ask for packaging compatibility data. Formula-to-pack interactions — airless pump elastomers, dropper bulbs, jar liners, fragrance–plastic contact — are a frequent late-stage failure. Request dosage reproducibility, viscosity range suitability and seal integrity results.
  • Ask for transit and leak simulation. Vibration, drop and altitude or pressure change results, plus a written statement on the maximum temperature excursion the pack has been tested to.
  • Ask for microbiological data. Preservative efficacy (challenge test), micro limits for the finished product, and the difference between single-use and multi-use formats.
  • Ask for the safety file contents. Product safety assessment, full INCI, allergen declaration, and impurity or heavy-metal data where pigments or active ingredients make it relevant.
  • Ask for manufacturing evidence. GMP certification (ISO 22716 or equivalent), batch records and a certificate of analysis per batch.

Label Questions GCC Buyers Should Ask Early

  • Language: Saudi Arabia requires Arabic, and bilingual Arabic/English labeling is the practical standard for the region. Confirm requirements for every other destination separately — they are not identical.
  • Responsible entity: importer or responsible-party name and address must be correct for each country. This field alone can force separate artwork versions.
  • Mandatory fields: INCI ingredient list, batch/lot code, expiry date or period after opening, net content, country of origin, warnings and directions in the required language.
  • Artwork space: reserve room for multi-country variants from the first design round. Retrofitting Arabic text into a finished layout is a common cause of reprints.
  • Consistency: the INCI on the printed label must match the INCI in the notification file, the COA and the website. Mismatches are the single most common documentation failure we see.
  • Claims placement: review the full pack, the product detail page and any advertising assets as one claim set, not as separate projects.

Notification, Responsibility and Post-Market Duties

  • Who files? For Saudi Arabia, confirm in writing whether the manufacturer, the importer or a regulatory agent submits the notification, and who holds the account on the unified electronic system.
  • What technical file supports the filing? Formula and INCI, safety documentation, label artwork and test reports should exist before the filing, not after.
  • Who owns complaints and adverse events? Post-market surveillance obligations sit with a named party. Request the adverse-event and complaint-handling procedure and the recall process before launch, not after the first customer email.

Minimum Evidence Pack to Request Before Approving a Formula

Document or test Why the buyer needs it Acceptance check
Signed formula and full INCI sheet Baseline for notification, labeling and COA reconciliation Version number and date match the artwork and the notification file
Accelerated and real-time stability report Supports the expiry date and shelf-life claim Includes elevated-temperature and cycling conditions relevant to GCC storage
Preservative efficacy (challenge) test Confirms micro safety for a multi-use jar or pump Method stated, pass criteria stated, product version identified
Packaging compatibility and seal integrity report Prevents leaks, pump failure and label lift in heat and humidity Tested with the actual formula and the actual pack, not a surrogate
Transit simulation / drop and leak results Protects the first shipment and the retail listing Conditions documented; failure modes photographed
Product safety assessment or safety file Required backbone of the regulatory submission Signed by a qualified assessor; covers the marketed concentration
Allergen declaration and fragrance documentation Drives label declarations and consumer-safety review Declared allergens cross-checked against the printed INCI
GMP certificate and per-batch COA Audit readiness and batch traceability Certificate valid on the planned production date; COA matches the shipped lot
Claims substantiation dossier Evidence for every statement on pack, PDP and ads Each approved claim maps to a named study or report

Where GCC Facial Skincare Projects Actually Slip

  • Symptom: cream separates, leaks or the pump stops dosing after a few weeks in market. Root cause: formula viscosity and the pump or valve were never tested together, and no elevated-temperature or humidity cycling was run. Prevention: lock the pack and run compatibility before artwork approval. Evidence to request: compatibility report, dosage reproducibility data, seal and leak results, pump supplier specification with viscosity range.
  • Symptom: label edges lift or print fades in a humid warehouse. Root cause: adhesive and varnish chosen for a temperate climate. Prevention: specify humidity- and heat-resistant adhesive at the artwork stage. Evidence to request: label supplier adhesion test report under elevated humidity.
  • Symptom: the notification is held or artwork is reprinted. Root cause: documentation failure — the INCI in the filed technical file, the COA and the printed label are three different versions. Prevention: version-lock the formula before artwork and run a three-way reconciliation. Evidence to request: signed formula/INCI sheet dated against the artwork, batch COA, and confirmation of which version was filed.
  • Symptom: a listing is pulled or copy has to be rewritten after launch. Root cause: claim drift — “reduces the appearance of redness” becomes “treats rosacea” in a creator brief. Prevention: an approved-claims matrix per market, with a copy sign-off step. Evidence to request: claims dossier plus written substantiation for each approved phrase.
  • Symptom: an allergen appears on the label but not in the safety file, or vice versa. Root cause: fragrance documentation was supplied late or from a different fragrance version. Prevention: freeze the fragrance version with the formula. Evidence to request: allergen declaration, fragrance supplier statement and GC-MS report tied to the exact fragrance code.
  • Symptom: no one can answer a customer reaction complaint. Root cause: no named responsible entity and no adverse-event procedure. Prevention: appoint the local responsible party before launch. Evidence to request: adverse-event and recall SOP with named contacts per market.

Do-Not-Cut Red Lines

  • Do not cut the elevated-temperature and cycling stability panel to save a month.
  • Do not cut packaging compatibility testing, even when the pack is a stock component.
  • Do not cut the preservative efficacy test on a multi-use jar or pump format.
  • Do not cut the three-way INCI reconciliation between file, COA and artwork.
  • Do not cut the claims-substantiation step to keep a launch date; reword the claim instead.
  • Do not accept “we are compliant worldwide” as a substitute for a per-country document set.

Frequently Asked Questions

Does GSO 1943:2024 cover every GCC market identically?

No. It provides a shared technical baseline, but notification, responsible-entity details and some labeling fields are determined nationally. Saudi Arabia runs through the SFDA unified electronic system; the UAE and other GCC states and emirates must be verified one by one.

Can we print one Arabic/English label for the whole region?

Sometimes, but only if the responsible-entity block, language requirements and mandatory fields are identical across your destination list. Most brands end up with at least two artwork versions, so reserve the space from the start.

Our product is already notified — does that clear our marketing claims?

No. Notification and claim approval are separate. Website copy, product names, images, before/after visuals and influencer scripts can all create claims that need their own substantiation, and a medical-sounding claim can change the product classification.

Is a patch test enough to support “hypoallergenic”?

Usually not. The claim needs a market-specific basis and appropriate evidence; a patch test alone can imply an absolute allergy-free promise that no formula can support. Confirm the wording for each destination before printing.

How long should we allow for testing?

Ask your laboratory for written lead times and plan artwork lock around them. Accelerated stability and microbiological testing are measured in months and weeks, not days, and re-running them after a formula change restarts the clock.

Next Step

If you are sourcing facial skincare for the Gulf, the fastest route to an accurate quote is to send your destination markets, SKU list and formats, positioning, packaging direction and target launch date in one message. We will map the classification route, the evidence pack and the label fields that apply to each country before you commit to tooling.

Request a Quote

Informational only, not legal advice. Confirm the regulatory route for each destination market with your responsible entity or qualified counsel.

Hi, I'm your LAEYO representative, hope you like this blog post.

With more than 20 years of experience in OEM/ODM/Private Label Cosmetics, I'd love to share valuable knowledge related to cosmetics & skincare products from a top-tier Chinese supplier's perspective.

  • Our team will answer your inquiries within 8 hours.
  • Your information will be kept strictly confidential.

Request received

Thanks — we’ve received your request. Our team will follow up shortly. we typically reply within 8 hours (often sooner).